Kymriah: England Becomes First In Europe To Say Yes To CAR-T

A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.

T-cells attacking cancer_1200x675
CAR-T therapy Kymriah could be made available to young patients in England in weeks

Novartis and the National Health Service in England have struck a deal on Kymriah (tisagenlecleucel) for use in children and young people with a certain form of leukemia, marking the first time a European country has agreed to fund access to a CAR-T therapy.

Announced today, the agreement comes less than 10 days after Novartis became one of the first two companies to receive...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet